Skip to main content
Elsevier

Current State of Alzheimer's and Parkinson's Disease Research and its Pharmacology

  • 1st Edition, Volume 108 - January 15, 2027
  • Latest edition
  • Editors: Subashchandrabose Chinnathambi, Diane Peters, Barbara S. Slusher
  • Language: English

Advances in Pharmacology series, highlights new advances in the field, with this new volume presenting interesting chapters. Each chapter is written by an international board… Read more

Description

Advances in Pharmacology series, highlights new advances in the field, with this new volume presenting interesting chapters. Each chapter is written by an international board of authors.

Key features

  • Provides the latest information on Pharmacology research: Current State of Alzheimer's and Parkinson's Disease Research and its Pharmacology
  • Offers outstanding and original reviews on a range of Pharmacology research topics
  • Serves as an indispensable reference for researchers and students alike

Readership

Clinicians, academicians, students, scientists

Table of contents

1. Tauopathies and its therapeutic interventions in Alzheimer’s disease
Subashchandrabose Chinnathambi

2. Biomarkers of Alzheimer's and Parkinson’s disease
Saroj Kumar

3. Pharmacological targets for Parkinson's disease
Abhishek Kumar Mishra and Dipak Kumar

4. Natural products in Parkinsons disease
S.P. Singh

5. Neurodegeneration of α-synuclein in Parkinson's disease
Meghana Tare

6. Targeting NLRP3 inflammasome for AD/PD
Gaurav Gupta

7. Pax6 in Alzheimer's and Parkinson's Disease
Rajnikant Mishra

8. Phamacological applications for AD/PD
Ashok Kumar Datusalia

9. Multitarget Approaches in the Treatment of Alzheimer's Disease: A New Strategy in Drug Design
Jemmyson Romário de Jesus

10. Phamacological applications for AD/PD
Ashok Kumar Datusalia

11. Podosomes in Alzheimer’s and Parkinson’s disease
Subashchandrabose Chinnathambi

12. Histone Deacetylases in Neurodegenerative/ Alzheimers diseases
Abhishek Balmik

13. Translational Pharmacological Interventions Targeting Amyloidogenic Mechanisms in Parkinson's Disease and Alzheimer's Disease
Mahesh Kandasamy

14. LRRK2 and Nrf2 Regulation in Parkinson’s Disease: Mechanistic Insights and Therapeutic Potential
Vijay Kumar Prajapati

15. Neural Receptors as the Gateway to Neuroprotection: The Current Landscape of Parkinson’s Therapeutics
Murugan Sevanan

16. Actin Cytoskeletal Pathology in Alzheimer’s Disease
Subashchandrabose Chinnathambi

17. Tau propagation models in AD
Ghulam Jeelani Pir

18. Nanoparticles targets for Alzheimer's and Parkinson's disease
Sharda Bharti

19. Signaling cascades of Chemokine receptors in Parkinson’s disease
Madhura Chandrashekar

20. Synaptic plasticity in Alzheimer’s disease
Poornima Priyadarshini

21. Cytokine synthesis and membrane-associated actin remodelling in AD microglia
Hariharakrishnan Chidambaram

22. Recent Advances in Biopolymeric Nanocarriers Based on Metallodrugs for Therapeutic Intervention in Neurodegenerative Diseases
Jemmyson Romário de Jesus

23. Modulating the Interactions between Amyloid-Beta, Tau, and Metals: Emerging Pharmacological Approaches in Alzheimer's Disease
Jemmyson Romário de Jesus

24. Pyk2 dysregulation in Alzheimer's disease
Aparna Banerjee Dixit

25. Are Lewy body dementia and Parkinson's disease dementia being the same thing, or are they different: the role of neurochemical bio markers
Subashchandrabose Chinnathambi

26. Blood-based biomarker analysis of Alzheimer’s disease by proteomics profiling
Subashchandrabose Chinnathambi

Product details

  • Edition: 1
  • Latest edition
  • Volume: 108
  • Published: January 15, 2027
  • Language: English

About the editors

SC

Subashchandrabose Chinnathambi

Subashchandrabose Chinnathambi is Additional Professor at the Department of Neurochemistry, National Institute of Mental Health and Neurosciences Hospital Bangalore, Karnataka, India. His scientific interests include physiopathology of neurodegenerative disorders, Tau Cytoskeleton, Tau-GPCR, purinergic and chemokine receptors, Tau stem cells, animal models, neuropharmacology, therapeutic approaches targeting Tau oligomers, and biomarkers for neurodegeneration. He serves on the editorial board for various international cell biology journals and is also a regular invited speaker at a number of meetings and workshops. Dr. Chinnathambi has more than 16 years of research experience in the area of neuroscience and Tau-related research in Alzheimer’s Disease.

Affiliations and expertise
Additional Professor, Department of Neurochemistry, National Institute of Mental Health and Neurosciences Hospital Bangalore, Karnataka, India

DP

Diane Peters

Diane Peters is an Assistant Professor of Pharmacology and Molecular Sciences at the Johns Hopkins School of Medicine. She received her BA in Chemistry, with honors, from Wellesley College, followed by pursuit of a PhD in Pharmacology and Experimental Therapeutics from the Tufts University School of Medicine. Subsequently, she earned an MS in laboratory animal medicine as well as a doctorate of veterinary medicine, both granted by the Tufts University School of Veterinary Medicine. Dr. Peters performed her post-graduate fellowship training in laboratory animal medicine at the Johns Hopkins University School of Medicine, where she further refined research expertise in comparative medicine, translational drug discovery, and animal pharmacology/toxicology.
Affiliations and expertise
Assistant Professor, Pharmacology and Molecular Sciences, Baltimore, MD, USA

BS

Barbara S. Slusher

Barbara Slusher is a Professor of Neurology (primary), Pharmacology and Molecular Sciences, Psychiatry, Neuroscience, Medicine, and Oncology at Johns Hopkins School of Medicine. She also serves as the Director of the Johns Hopkins Drug Discovery, the Vice Director of the Pedersen Brain Science Institute, and the Co-Director of the Johns Hopkins Center for the Advancement of HIV Neurotherapeutics (JH CAHN). She has published over 300 scientific articles and is an inventor on over100 patents and applications. Before joining Johns Hopkins, she spent 18 years in the pharmaceutical industry, including several years at the level of Senior Vice President of Research and Translational Development. She has extensive experience in drug discovery through early clinical development and was involved in the successful development, launch and/or post marketing support of several FDA-approved medicines. In 2010, she joined Johns Hopkins to lead the largest drug discovery program on campus with a veteran team of over 25 medicinal chemists, assay developers, pharmacologists, toxicologists, and pharmacokinetics/drug metabolism experts. The team identifies novel drug targets and translates them into new drug therapies for clinical development. Since joining JHU, she has co-founded four new companies which have amassed over $150M in financing and has partnered four new drug discovery programs with Pharma. She also founded the first International Consortium of Academic Drug Discovery Centers (http://addconsortium.org/) with over 150 university-led translational centers and 1500 members to bring together this growing community. Dr. Slusher received her undergraduate degree from Dickinson College where she graduated valedictorian, majoring in Chemistry. She received her Ph.D. in Pharmacology and Molecular Sciences from the Johns Hopkins School of Medicine while simultaneously earning her Master's degree in Administrative Science from the Johns Hopkins Carey School of Business (formerly School of Continuing Studies).
Affiliations and expertise
Professor of Neurology, Pharmacology, Psychiatry, Neuroscience, Medicine, and Oncology Director, Johns Hopkins Drug Discovery Vice Director, Pederson Brain Science Institute Johns Hopkins School of Medicine, MD, USA